Celldex Q4 net loss $20.1M; CDX-0159 Phase 2 urticaria studies to start Q2 2022

Celldex Therapeutics, Inc.

2021-FY EPS reported -$1.64 revenue$4,651,000

Net loss of $20.1M ($0.43 diluted EPS) for Q4 2021; full year net loss $70.5M ($1.64 EPS).
Cash and marketable securities $408.3M as of Dec 31, 2021; provides runway through 2025.
CDX-0159 Phase 1b CSU data expected July 2022; Phase 2 studies in CSU and CIndU to initiate Q2 2022.
Plans to expand CDX-0159 development into eosinophilic esophagitis (EoE) with Phase 2 trial in Q4 2022.
Subcutaneous formulation of CDX-0159 well tolerated; supports planned Phase 2 doses of 75mg, 150mg, 300mg.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.